Senior Management
Discover the exceptional team behind Cumberland Biotherapeutics, committed to revolutionizing healthcare with groundbreaking solutions and pioneering research. Get acquainted with the passionate individuals driving progress in the field.
David Dancy
David Dancy joined Cumberland Biotherapeutics as Head of Global Operations and Chief Financial Officer in 2021. With over 10 years of experience in the healthcare industry, he brings a unique perspective shaped by his executive and managerial roles across health insurance, real estate, land surveying, and property development. David holds a B.S. in Organizational Management and an MBA.
In his healthcare career, David successfully oversaw new product implementation for Tennessee’s Medicaid division. Prior to joining Cumberland, he served in the U.S. Marine Corps and the U.S. Army as a noncommissioned officer. David became part of the Cumberland Biotherapeutics team in 2020, playing a pivotal role in launching their flagship product, DentoClude F.
Danny Dancy
Danny Dancy, Head of CMC, Quality & Compliance. Danny owned and operated his company, Tennessee Valley Engineer Surveying since 1981, conducting land surveys and overseeing property development projects. Danny holds licenses in Tennessee, Alabama, Georgia and Mississippi, working in numerous partnerships developing properties.
Danny has extensive experience overseeing all aspects of operations, quality assurance, compliance, demonstrating his expertise in budgetary discipline, time-line management and inventory control. Danny joined Cumberland Biotherapeutics in 2021 using his experience to take a project from inception to market on time and on budget.
Dr. Sireesha
Dr. Sireesha Peddireddi joined Cumberland Biotherapeutics in 2022, bringing extensive experience in healthcare and multinational pharmaceutical companies. A licensed dentist, Dr. Peddireddi has expertise in clinical research, personnel management, and the drug discovery and development process.
She has successfully led teams managing regulatory submissions for product registration in numerous countries, including the USA, Russia, China, India, South Africa, and more. Dr. Peddireddi holds a Bachelor’s degree in Dental Surgery from Bangalore University and a Master’s Certification in Clinical Research & Clinical Data Management from Pune University.
Board of Directors
Discover the exceptional team behind Cumberland Biotherapeutics, committed to revolutionizing healthcare with groundbreaking solutions and pioneering research. Get acquainted with the passionate individuals driving progress in the field.
Vivekananda Ramana, M.D. Interim CEO
University of Belgrade (Serbia), Yugoslavia – speciality Radiation Oncology/ Clinical Pathology, 1982; Residency 1985 – Military Medical Academy Hospital/ Belgrade, Yugoslavia; Kalos Institute for Medicine and Rehabilitation Vela Luka, Yugoslavia. Tufts University School of Medicine – 2002; Clinical Pharmacology, Drug Development, and Regulation
More the 25 years, highly experienced in Clinical Drug Development & Safety/ Pharmacovigilance Executive with a demonstrated track record in pharmaceuticals and biotechnology clinical research having worked on the full-scale production (Pre-clinical, Phase 1 – 1V, and Post Marketing) for over 60 drugs in therapeutic areas such as Oncology/ Haematology, Infectious Disease, CNS, Cardio-Vascular, Transplant Immunology, Dermatology, Rare Diseases/ Neurology, Medical Devices etc. Proven competencies as multi-tiered project manager, clinical research scientist, senior medical director, drug safety & pharmacovigilance safety medical officer, vice president of medical services and Chief Medical Officer.
Managed major clinical studies and possess in-depth knowledge of clinical and drug trials NDA and MAA filing, FDA and international regulations and guidelines. During his tenure in the pharmaceutical industry, he worked at Bristol Meyers Squibb, AstraZeneca, Pfizer, Schering-Plough, US Astellas, Ambit Bioscience, Incyte Corporation, Therapeutics, Akcea Therapeutics, Fulcrum Therapeutics etc
Vivekananda Ramana, M.D. Interim CEO
Ralph T. Salvagno, M.D.
Orthopaedic Surgeon, 37-year Orthopaedic Surgery career has focused upon the treatment of degenerative and traumatic musculoskeletal conditions particularly in the field of total joint arthroplasty and adult reconstructive surgery.
As a joint reconstruction surgeon, many of the issues I encountered were related to bone biology, particularly bone resorption associated with implants. Orthopaedics has always borrowed liberally from the field of dentistry and dental surgery.
My interest in bone biology and musculoskeletal physiology has led me to my work as principal Investigator of two industry sponsored studies. I have a close affiliation with a major University which provides access to academic expertise in multiple fields of medicine. I currently serve as CEO of two start up Biopharmaceutical companies based on my experience and expertise in drug development and financial management.
As a joint reconstruction surgeon, many of the issues I encountered were related to bone biology, particularly bone resorption associated with implants. Orthopaedics has always borrowed liberally from the field of dentistry and dental surgery.
My interest in bone biology and musculoskeletal physiology has led me to my work as principal Investigator of two industry sponsored studies. I have a close affiliation with a major University which provides access to academic expertise in multiple fields of medicine. I currently serve as CEO of two start up Biopharmaceutical companies based on my experience and expertise in drug development and financial management.
Marc Cantillon, M.D
36 years of experience in the medical field. He graduated from Karolinska Institutet, Medicinska Fakulteten Stockholm, Sweden in 1987.He completed further training in medicine at Cornell and neurology/ psychiatry at Mt. Sinai Beth Israel in New York City
Dr. Cantillon is an experienced senior biopharmaceutical leader who has overseen global clinical development programs across different therapeutic areas through phases 0 to IV, with global program oversight of orphan indications. He was most recently Chief Medical Officer of Reviva Pharmaceuticals, a genomics based company with a focus on CNS and metabolic disease, where he was responsible for transitional clinical development, regulatory filings,orphan drug and IP registrations. Prior to this, Dr. Cantillon was Chief Medical Officer of Green Valley Pharmaceuticals, a biopharmaceutical company developing carbohydrate drugs in Parkinsons’s Disease (PD) and Alzheimer’s Disease (AD). Dr. Cantillon has held a variety of senior positions throughout his career at leading biotech and pharmaceutical companies, including leadership roles at AstraZeneca in neuropsychiatric disorders and migraine. He was also involved in the development of a PD medication as CMO at Impax Labs; the development of a PD medication at Kyowa Kirin as CNS Development Lead of Japan, US and Europe; and VP CNS Clinical Research and Translational Therapeutic Area Lead at Merck (Schering). As Global Therapeutic Area Lead for Wyeth (Pfizer), Dr. Cantillon contributed to product development activities across multiple mood disorders, insomnia and the joint venture with Athena to conduct the innovative first immunotherapy vaccine trial in AD. Earlier in his career, Dr. Cantillon was the North American Medical Director at Sanofi.
Dr. Cantillon is an experienced senior biopharmaceutical leader who has overseen global clinical development programs across different therapeutic areas through phases 0 to IV, with global program oversight of orphan indications. He was most recently Chief Medical Officer of Reviva Pharmaceuticals, a genomics based company with a focus on CNS and metabolic disease, where he was responsible for transitional clinical development, regulatory filings,orphan drug and IP registrations. Prior to this, Dr. Cantillon was Chief Medical Officer of Green Valley Pharmaceuticals, a biopharmaceutical company developing carbohydrate drugs in Parkinsons’s Disease (PD) and Alzheimer’s Disease (AD). Dr. Cantillon has held a variety of senior positions throughout his career at leading biotech and pharmaceutical companies, including leadership roles at AstraZeneca in neuropsychiatric disorders and migraine. He was also involved in the development of a PD medication as CMO at Impax Labs; the development of a PD medication at Kyowa Kirin as CNS Development Lead of Japan, US and Europe; and VP CNS Clinical Research and Translational Therapeutic Area Lead at Merck (Schering). As Global Therapeutic Area Lead for Wyeth (Pfizer), Dr. Cantillon contributed to product development activities across multiple mood disorders, insomnia and the joint venture with Athena to conduct the innovative first immunotherapy vaccine trial in AD. Earlier in his career, Dr. Cantillon was the North American Medical Director at Sanofi.
Krishna Reddy, DDS
A practicing dentist with 18 years of academic and clinical experience. Dr. Reddy has published more than 25 scientific research article publications in reputed international and national specialty journals.
Dr. Krishna Reddy is a Professor with the Department of Periodontics at Sri Sai College of Dental Surgery, Vikarabad, Telangana. Dr. Reddy is also a Consultant Periodontist and Dental Implantologist with the Sri Harsha Dentofacial Center, Hyderabad, India.
Dr. Krishna Reddy is a Professor with the Department of Periodontics at Sri Sai College of Dental Surgery, Vikarabad, Telangana. Dr. Reddy is also a Consultant Periodontist and Dental Implantologist with the Sri Harsha Dentofacial Center, Hyderabad, India.
Clifford Price, CMO
Clifford Price: Founder Ysolutions LLC., CMO LigoFlex Gobal Markets, Artificial Intelligence Developer and Consultant, Sales and Marketing Expert
Clifford Price is an accomplished sales and marketing expert with over three decades of experience driving corporate success. As an Intelligence Analyst, he brings a unique perspective and deep understanding of market trends and competitive landscapes to his work. Clifford’s exceptional reputation in the industry is reflected in his receiving the highly coveted 2020 Best Corporate Communications, Sales & Marketing Consultancy Award in California by CV Magazine and the International Trade Council Award and Membership. Expertise and Achievements. He also has served as the North American United States Artificial Intelligence Consultant since 2021.
© Copyright CBT 2025. All rights reserved